Kathleen Essel, MD

Kathleen Essel, MD, a fellow at University of Oklahoma Health Science Center, discusses the findings from a recent trial investigating the safety of long-term treatment with bevacizumab (Avastin) in patients with ovarian cancer.

Essel says the results from this trial can provide a lot of comfort, since patients who did well initially on this treatment subsequently did well later on. Findings demonstrated that adverse effects found during initial treatment did not worsen later on.

Videos

Kathleen Essel, MD, a fellow at University of Oklahoma Health Science Center, discusses the findings from a recent trial investigating the safety of long-term treatment with bevacizumab in patients with ovarian cancer.&nbsp;

Kathleen Essel, MD | Authors

Articles

Safety Findings of Long-Term Bevacizumab for Patients with Ovarian Cancer